Compare AstraZeneca plc (AZN) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? AstraZeneca plc trades at $158.6 (market cap $248.14B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.13. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AZN | LQD | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $112.91 |
52-Week Low | $147.06 | $105.96 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
LQD trades at $106.215, up 0.24% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings while facing pressure from rising Treasury yields and inflation concerns. Recent dividend distributions provide income support, but technical indicators suggest caution with 17 sell signals versus 2 buy signals.
The outlook remains challenged by bond market volatility and Fed policy uncertainty. Investment opportunities exist for income-focused investors through dividends, but risks include interest rate sensitivity and macroeconomic pressures from oil price fluctuations and geopolitical tensions affecting fixed income markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
